Drug profile · INN
tisagenlecleucel
KYMRIAH
tisagenlecleucel (KYMRIAH) is a b-lymphocyte antigen cd19 binding agent.
Drug details — tisagenlecleucel
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
tisagenlecleucel (KYMRIAH) is a b-lymphocyte antigen cd19 binding agent.
Key facts
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
CAR-T Cell Therapy Europe: Clinical Trials, Safety & Market Access Insights
Discover the latest insights on CAR-T Cell Therapy in Europe, focusing on clinical trials, safety profiles, and market access for hematologic cancers.
CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape
This article delves into CAR-T cell therapy in Japan, highlighting regulatory frameworks and the evolving clinical trial landscape for hematologic malignancies.
CAR-T Access EU Policy: Impact of Cross-Border Healthcare on Advanced Therapies
This article examines the implications of cross-border healthcare policies on CAR-T therapies for cancer, highlighting access challenges and opportunities in the EU.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tisagenlecleucel?
tisagenlecleucel (KYMRIAH) is a b-lymphocyte antigen cd19 binding agent.
What is the brand name for tisagenlecleucel?
KYMRIAH is a marketed brand name for tisagenlecleucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.